Open AccessEffectiveness of a novel, fixed dose combination of netupitant and palonosetron in prevention of chemotherapy induced nausea and vomiting: A real-life study from India
Author(s) -
Bharat Vaswani,
Sagar Bhagat,
Saiprasad Patil,
Hanmant Barkate
Publication year - 2020
Publication title -
world journal of clinical oncology
Language(s) - English
Resource type - Journals
ISSN - 2218-4333
DOI - 10.5306/wjco.v11.i8.606
Subject(s) - palonosetron , chemotherapy induced nausea and vomiting , medicine , nausea , aprepitant , vomiting , chemotherapy , gastroenterology , anesthesia , oncology , antiemetic
A new, oral fixed dose combination of highly selective neurokinin-1 receptor antagonist, netupitant with 5HT3 receptor antagonist, netupitant and palonosetron (NEPA) was approved in India for prevention of chemotherapy induced nausea and vomiting (CINV).